Back to Search
Start Over
A randomized, double-blind, placebo-controlled, repeated-dose pilot study of the safety, tolerability, and preliminary effects of a cannabidiol (CBD)- and cannabigerol (CBG)-based beverage powder to support recovery from delayed onset muscle soreness (DOMS).
- Source :
-
Journal of the International Society of Sports Nutrition [J Int Soc Sports Nutr] 2023 Dec; Vol. 20 (1), pp. 2280113. Date of Electronic Publication: 2023 Nov 10. - Publication Year :
- 2023
-
Abstract
- Background: Cannabinoid-containing products are marketed to athletes as promoting recovery, in spite of a lack of data on their safety and effects. This randomized, double-blind, placebo-controlled, repeated-dose pilot study tested the safety, tolerability, and preliminary effects on recovery of a formulation containing cannabidiol (CBD; 35 mg), cannabigerol (CBG; 50 mg), beta caryophyllene (BCP; 25 mg), branched-chain amino acids (BCAAs; 3.8 g), and magnesium citrate (420 mg).<br />Methods: Exercise-trained individuals ( N = 40) underwent an experimental induction of delayed onset muscle soreness (DOMS) and completed follow-up visits 24-, 48-, and 72-hours post-DOMS. Participants were randomized to active or placebo formulation, and consumed the formulation twice per day for 3.5 days.<br />Results: There was one adverse event (AE) in the active group (diarrhea) and two AEs in placebo (dry mouth; eye rash/swollen eye). There was 100% self-reported compliance with formulation consumption across the two groups. For the primary outcome of interest, the estimate of effect for ratings of average soreness/discomfort 72 hours post-DOMS between active and placebo groups was -1.33 (85% confidence interval = -2.55, -0.10), suggesting moderate evidence of a treatment difference. The estimate of effect for the outcome of ratings of interference of soreness, discomfort, or stiffness on daily activities at work or home 48 hours post-DOMS was -1.82 (95% confidence interval = -3.64, -0.01), indicating a treatment difference of potential clinical importance. There was no significant effect between active and placebo groups on objective measures of recovery, sleep quality, or mood disturbance.<br />Conclusions: The tested formulation reduced interference of DOMS on daily activities, demonstrating its improvement on a functional aspect of recovery.
- Subjects :
- Humans
Pilot Projects
Powders
Myalgia drug therapy
Cannabidiol therapeutic use
Subjects
Details
- Language :
- English
- ISSN :
- 1550-2783
- Volume :
- 20
- Issue :
- 1
- Database :
- MEDLINE
- Journal :
- Journal of the International Society of Sports Nutrition
- Publication Type :
- Academic Journal
- Accession number :
- 37947792
- Full Text :
- https://doi.org/10.1080/15502783.2023.2280113